JP2023513693A5 - - Google Patents

Info

Publication number
JP2023513693A5
JP2023513693A5 JP2022548435A JP2022548435A JP2023513693A5 JP 2023513693 A5 JP2023513693 A5 JP 2023513693A5 JP 2022548435 A JP2022548435 A JP 2022548435A JP 2022548435 A JP2022548435 A JP 2022548435A JP 2023513693 A5 JP2023513693 A5 JP 2023513693A5
Authority
JP
Japan
Prior art keywords
cov
immunogen
protomer
amino acid
ectodomain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022548435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513693A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/017709 external-priority patent/WO2021163365A1/en
Publication of JP2023513693A publication Critical patent/JP2023513693A/ja
Publication of JP2023513693A5 publication Critical patent/JP2023513693A5/ja
Priority to JP2025272749A priority Critical patent/JP2026040566A/ja
Withdrawn legal-status Critical Current

Links

JP2022548435A 2020-02-11 2021-02-11 SARS-CoV-2ワクチン Withdrawn JP2023513693A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025272749A JP2026040566A (ja) 2020-02-11 2025-12-22 SARS-CoV-2ワクチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062972886P 2020-02-11 2020-02-11
US62/972,886 2020-02-11
PCT/US2021/017709 WO2021163365A1 (en) 2020-02-11 2021-02-11 Sars-cov-2 vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025272749A Division JP2026040566A (ja) 2020-02-11 2025-12-22 SARS-CoV-2ワクチン

Publications (2)

Publication Number Publication Date
JP2023513693A JP2023513693A (ja) 2023-04-03
JP2023513693A5 true JP2023513693A5 (https=) 2024-02-20

Family

ID=74860458

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022548435A Withdrawn JP2023513693A (ja) 2020-02-11 2021-02-11 SARS-CoV-2ワクチン
JP2025272749A Pending JP2026040566A (ja) 2020-02-11 2025-12-22 SARS-CoV-2ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025272749A Pending JP2026040566A (ja) 2020-02-11 2025-12-22 SARS-CoV-2ワクチン

Country Status (11)

Country Link
US (1) US20230113170A1 (https=)
EP (1) EP4103229A1 (https=)
JP (2) JP2023513693A (https=)
KR (1) KR20220140586A (https=)
CN (1) CN115515627A (https=)
AU (1) AU2021221127A1 (https=)
BR (1) BR112022015628A2 (https=)
CA (1) CA3170322A1 (https=)
IL (2) IL295301A (https=)
MX (1) MX2022009836A (https=)
WO (1) WO2021163365A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210260181A1 (en) * 2014-09-16 2021-08-26 Altimmune, Inc Coronavirus immunogenic compositions and uses thereof
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
EP4103231A4 (en) 2020-02-14 2024-03-27 Geovax, Inc. VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2
WO2021170869A1 (en) * 2020-02-27 2021-09-02 Katholieke Universiteit Leuven Coronavirus vaccines
IL297419B2 (en) * 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
KR20230116810A (ko) * 2020-11-03 2023-08-04 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 Dna 암호화 나노입자 및 코로나바이러스 질환 2019(covid-19) 백신으로서의 그것의 사용 방법
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
CN113633764B (zh) * 2021-09-02 2024-05-14 中国食品药品检定研究院 一种含佐剂的新冠dna疫苗
CN113527522B (zh) * 2021-09-13 2021-12-21 深圳市瑞吉生物科技有限公司 一种新冠病毒三聚体重组蛋白、DNA、mRNA及应用和mRNA疫苗
CN115806624A (zh) * 2021-09-14 2023-03-17 中国人民解放军陆军军医大学第一附属医院 融合新冠病毒亚单位蛋白和IgG1-Fc区域的蛋白及在疫苗开发中的用途
WO2023047348A1 (en) * 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023047349A1 (en) * 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023067193A2 (en) 2021-10-22 2023-04-27 BioNTech SE Compositions for administration of different doses of rna
EP4436595A1 (en) 2021-11-22 2024-10-02 Pfizer Inc. Reducing risk of antigen mimicry in immunogenic medicaments
AU2022398292A1 (en) 2021-11-29 2024-06-13 BioNTech SE Coronavirus vaccine
US20230167157A1 (en) * 2021-11-29 2023-06-01 Arabian Gulf University ANTIGENIC DETERMINANTS PROTECTIVE IMMUNITY, SERODIAGNOSTIC AND MULTIVALENT SUBUNITS PRECISION VACCINE AGAINST SARS-CoV-2
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CN114989308B (zh) * 2022-05-12 2023-04-04 中国科学院微生物研究所 新冠病毒嵌合核酸疫苗及其用途
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
CN115287265B (zh) * 2022-07-12 2023-05-23 四川大学华西医院 多能活性制剂诱发恒河猴抵抗新冠突变体的免疫防治模型
WO2024086575A1 (en) 2022-10-17 2024-04-25 BioNTech SE Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
KR20260015501A (ko) * 2024-07-25 2026-02-03 아주대학교산학협력단 다중 에피토프 기반 사스코로나바이러스-2 백신 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
SK282843B6 (sk) 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
JP2005503797A (ja) 2001-09-13 2005-02-10 ジェンベク、インコーポレイティッド アデノウイルスベクター及び関連する系、並びに製造及び使用の方法
US10960070B2 (en) * 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
WO2019241483A1 (en) * 2018-06-13 2019-12-19 The Scripps Research Institute Nanoparticle vaccines with novel structural components

Similar Documents

Publication Publication Date Title
JP2023513693A5 (https=)
US12162909B2 (en) Subunit vaccine for treatment or prevention of a respiratory tract infection
US11229694B2 (en) Vaccine against RSV
US20230340031A1 (en) Self-assembling protein nanoparticles with built-in six-helix bundle proteins
JP2023544834A5 (https=)
AU2021232702B2 (en) Stabilized pre-fusion RSV F proteins
JP2012533558A5 (https=)
TW202130363A (zh) 變異型rsv f蛋白質及其利用
WO2017207477A1 (en) Stabilized pre-fusion rsv f proteins
RU2811991C2 (ru) Субъединичная вакцина для лечения или предотвращения инфекции дыхательных путей
KR20260035821A (ko) 조작된 gcn4 삼량체화 모티프
HK40051815A (en) Vaccine against rsv comprising modified f polypeptide
OA19273A (en) Stabilized pre-fusion RSV F proteins.
HK40000138B (en) Stabilized pre-fusion rsv f proteins
HK40000138A (en) Stabilized pre-fusion rsv f proteins
HK1250939B (en) Vaccine against rsv